| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3864578 | The Journal of Urology | 2014 | 6 Pages |
Abstract
BC-819 prevented new tumor growth in two-thirds of the patients and ablated a third of the marker lesions. Prolonged time to recurrence was observed in responding patients. These results along with the good safety profile make BC-819 a potential medication for bladder cancer.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Ofer N. Gofrit, Shalva Benjamin, Sarel Halachmi, Ilan Leibovitch, Zohar Dotan, Donald L. Lamm, Nahum Ehrlich, Vladimir Yutkin, Monique Ben-Am, Abraham Hochberg,